# Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.

> PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42592044-maridebart-cafraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42592044-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42592044-maridebart-cafraglutide-v1.json
- Content SHA-256: `9459fb0491690210e2de13010f9740165bf6e4cc5175eb00fb9a085687124525`

## Claims and source pins

### Headline

Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

### Summary

PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

### Paragraph 1

PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`](#source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671))

## Sources

<a id="source-pubmed-observation-pmid-42592044-2026-08-13-41bdad779671"></a>
- **Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. · retained source version 1:2026-08-13:current:41bdad7796714760059177aeeebb9c4217b2973c075002cc8d757619c91b8b6e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42592044/) (`pubmed-observation-pmid-42592044-2026-08-13-41bdad779671`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42592044-maridebart-cafraglutide-v1.json SHA-256: 9459fb0491690210e2de13010f9740165bf6e4cc5175eb00fb9a085687124525.